Gilead Sciences
3 Heritage Way
Suite 4
Gloucester
MA
01930
United States
Tel: 617299-8889
5 articles about Gilead Sciences
-
China’s National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6
12/4/2018
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the National Medical Products Administration (NMPA) has approved Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) in China for the treatment of chronic hepatitis C virus (HCV) genotype 1-6 infection in adults and adolescents aged 12 to 18 years.
-
TARGET PharmaSolutions® to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead Sciences
11/20/2018
TARGET PharmaSolutions, Inc., a company focused on real world evidence, is pleased to announce that it has entered into a strategic partnership with Gilead Sciences for TARGET-NASH and TARGET-HBV.
-
China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection
11/19/2018
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Medical Products Administration (NMPA) has approved Vemlidy® (tenofovir alafenamide, TAF) 25 mg, a once-daily treatment for chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).
-
Gilead Sciences Announces Third Quarter 2018 Financial Results
10/25/2018
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter ended September 30, 2018.
-
Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018
10/11/2018
- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that data from the company’s liver disease research and development programs in nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection will be presented at The Liver Meeting® 2018